Literature DB >> 15616164

RHO SIGNALING in vascular diseases.

Tammy M Seasholtz1, Joan Heller Brown.   

Abstract

Rho signaling pathways in vascular smooth muscle cells are highly activated in hypertension, a condition associated with a variety of vascular diseases, including restenosis injury and atherosclerosis. In this review we suggest that inflammatory cytokines and agonists of G protein-coupled receptors that activate Rho are effective triggers of vascular disease. Accordingly, Rho kinase inhibitors and statins may have therapeutic potential for preventing vascular disease characterized by Rho-mediated cell proliferation and gene expression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15616164     DOI: 10.1124/mi.4.6.8

Source DB:  PubMed          Journal:  Mol Interv        ISSN: 1534-0384


  20 in total

1.  Low-dose irradiation causes rapid alterations to the proteome of the human endothelial cell line EA.hy926.

Authors:  Franka Pluder; Zarko Barjaktarovic; Omid Azimzadeh; Simone Mörtl; Anne Krämer; Sylvia Steininger; Hakan Sarioglu; Dariusz Leszczynski; Reetta Nylund; Arvi Hakanen; Arundhathi Sriharshan; Michael J Atkinson; Soile Tapio
Journal:  Radiat Environ Biophys       Date:  2010-11-23       Impact factor: 1.925

2.  CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion.

Authors:  Mohanraj Rajesh; Partha Mukhopadhyay; Sándor Bátkai; György Haskó; Lucas Liaudet; John W Huffman; Anna Csiszar; Zoltan Ungvari; Ken Mackie; Subroto Chatterjee; Pál Pacher
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-07-27       Impact factor: 4.733

3.  Dynamics of neutrophil extravasation and vascular permeability are uncoupled during aseptic cutaneous wounding.

Authors:  Min-Ho Kim; Fitz-Roy E Curry; Scott I Simon
Journal:  Am J Physiol Cell Physiol       Date:  2009-01-28       Impact factor: 4.249

4.  p63RhoGEF couples Gα(q/11)-mediated signaling to Ca2+ sensitization of vascular smooth muscle contractility.

Authors:  Ko Momotani; Mykhaylo V Artamonov; Darkhan Utepbergenov; Urszula Derewenda; Zygmunt S Derewenda; Avril V Somlyo
Journal:  Circ Res       Date:  2011-09-01       Impact factor: 17.367

5.  End-organ protection in hypertension by the novel and selective Rho-kinase inhibitor, SAR407899.

Authors:  Matthias Löhn; Oliver Plettenburg; Aimo Kannt; Markus Kohlmann; Armin Hofmeister; Dieter Kadereit; Peter Monecke; Alexander Schiffer; Anke Schulte; Hartmut Ruetten; Yuri Ivashchenko
Journal:  World J Cardiol       Date:  2015-01-26

Review 6.  Transcription factor and kinase-mediated signaling in atherosclerosis and vascular injury.

Authors:  Neeta Adhikari; Nathan Charles; Ute Lehmann; Jennifer L Hall
Journal:  Curr Atheroscler Rep       Date:  2006-05       Impact factor: 5.113

Review 7.  p63RhoGEF: a new switch for G(q)-mediated activation of smooth muscle.

Authors:  Ko Momotani; Avril V Somlyo
Journal:  Trends Cardiovasc Med       Date:  2012-08-16       Impact factor: 6.677

Review 8.  G protein-coupled receptors go extracellular: RhoA integrates the integrins.

Authors:  Colin T Walsh; Dwayne Stupack; Joan Heller Brown
Journal:  Mol Interv       Date:  2008-08

9.  Differential regulation of RhoA-mediated signaling by the TPalpha and TPbeta isoforms of the human thromboxane A2 receptor: independent modulation of TPalpha signaling by prostacyclin and nitric oxide.

Authors:  Katarina Wikström; David J Kavanagh; Helen M Reid; B Therese Kinsella
Journal:  Cell Signal       Date:  2008-05-23       Impact factor: 4.315

10.  Losartan counteracts the hyper-reactivity to angiotensin II and ROCK1 over-activation in aortas isolated from streptozotocin-injected diabetic rats.

Authors:  Paola Failli; Chiara Alfarano; Sergio Franchi-Micheli; Edoardo Mannucci; Elisabetta Cerbai; Alessandro Mugelli; Laura Raimondi
Journal:  Cardiovasc Diabetol       Date:  2009-06-22       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.